James I. Geller, MD, started in the Division of Oncology at Cincinnati Children's Hospital Medical Center as an assistant professor within the UC Department of Pediatrics in 2004. Currently, he is the medical director of Liver and Renal Tumor Programs and co-director of the Retinoblastoma Program.
His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, he achieves this through direct patient care and by leading our teams in clinical and research efforts in my specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, he participates as a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor, Retinoblastoma and Central Nervous System Committees; He functions as vice chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as chair both the RTC Developmental Therapeutics Working Group and the COG High Risk Renal Tumors Protocols including AREN1721 (focused on immunotherapy and anti-angiogenic therapy for TFE Renal Cell Carcinoma), AREN1921 (focused on relapsed and anaplastic Wilms tumor), and has drafted the next concept for study of epigenetic therapy plus chemotherapy for treatment of rhabdoid tumor. He also serves as co-chair of the COG liver tumor protocol, the Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.
It is his goal to help facilitate the development of novel therapy for young patients affected with solid tumors. Current areas of expansion include the establishment of the Translational RCC Research Initiatives including a registry for TFE RCC, and development of data harmonization and treatment optimization for relapsed pediatric liver cancers. Integration of cellular and immunotherapy, as well as novel interventional therapeutics, remains a priority.
BA: Chemistry, Dartmouth College, Hanover, NH.
MD: Sackler School of Medicine, Tel Aviv University, 1997.
Residency: Pediatrics, New York Medical College, 2000.
Fellowship: Pediatric Hematology/Oncology, St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000, 2007; Pediatric Hematology/Oncology, 2005.
Pediatric oncology; solid tumors; liver tumors; kidney tumors; retinoblastoma; rare tumors; intraarterial chemotherapy and intraarterial radiotherapy for treatment of select cancers
Cancer and Blood Diseases, Kidney Tumor, Liver Tumor, Pancreas Care
Liver tumors; kidney tumors; retinoblastoma; new drug development; novel interventional therapeutics: intra-arterial chemotherapy, intra-arterial radiotherapy, high intensity focused ultrasound (HIFU)
Oncology, Cancer and Blood Diseases
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group. Radiology. 2013; 266:610-617.
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. Journal of Hepatology. 2022; 77:1026-1037.
β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma. Hepatology Communications. 2022; 6:2950-2963.
Pediatric Renal Tumors. Pediatric Nephrology. 2022.
Skeletal muscle mass as a marker to predict outcomes in children and young adults with cancer. Abdominal Radiology. 2022; 47:452-459.
Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer. American Journal of Roentgenology. 2021; 217:1444-1451.
Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Communications Biology. 2021; 4.
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Hepatology. 2021; 74:2201-2215.
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncology. 2021; 7:1550-1558.
James I. Geller, MD, David S. Cooper, MD, MPH ...3/20/2022
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey